CACNB2 Polyclonal Antibody
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-2996R |
| Product Name | CACNB2 Polyclonal Antibody |
| Applications |
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CACNB2 |
| Immunogen Range | 551-655/655 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 783 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | Voltage-dependent L-type calcium channel subunit beta-2; CAB2; Cacnb2; Cacnlb2; VDCC-L Beta; Calcium channel voltage-dependent subunit beta 2; calcium channel, voltage-dependent, beta 2 subunit; calcium channel beta 2c subunit; calcium channel L-type beta 2 subunit; CACB2_HUMAN. |
| Background | CACNB2 is a subunit of a voltage-dependent calcium channel protein which is a member of the voltage-gated calcium channel superfamily, expressed in the CNS. The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting. It was originally identified as an antigen target in Lambert-Eaton myasthenic syndrome which is an autoimmune disorder. Mutations in this gene are associated with Brugada symdrome. Alternatively spliced variants have been identified for this gene. |
| Application Dilution | |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |